/
GNPX
$0.51+$0.01 (+2.06%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.4M
11M shares
52-week range
$0.42 – $55.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
12.30%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-6699.49
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5.9K | $13.1K | $22.8K | $22.5K | $25.6K | $15.0K | $6.7K | $0 |
| Gross profit | −$5.9K | −$13.1K | −$22.8K | −$22.5K | −$25.6K | −$15.0K | −$6.7K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $971.4K | $2.0M | $7.3M | $9.0M | $11.5M | $17.6M | $10.5M | $9.4M |
| Operating income | −$12.4M | −$10.7M | −$18.0M | −$20.7M | −$23.8M | −$31.1M | −$21.2M | −$15.5M |
| EBITDA | −$12.3M | −$10.6M | −$17.9M | −$20.6M | −$23.7M | −$30.8M | −$21.1M | −$15.5M |
| Net income | −$12.4M | −$10.7M | −$17.9M | −$20.7M | −$23.7M | −$30.9M | −$21.1M | −$16.2M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1797.00 | -1329.50 | -1009.00 | -877.50 | -990.00 | -1128.00 | -266.95 | -17.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-57.50 | $-57.50–$-57.50 | 1 |
| 2027 | $0 | $-480.00 | $-480.00–$-480.00 | 1 |
| 2028 | $0 | $-10.80 | $-10.80–$-10.80 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.64
Price
$0.51
Implied upside
+1412%
Peer comparison
Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
www.genprex.com- Employees
- 13
- IPO / List date
- Mar 29, 2018
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds GNPX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GNPX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-10-21 | 1-for-50reverse |
| 2024-02-02 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded GNPX yet.
